

University of Groningen

Mechanisms of TRAIL-resistance

Zhang, Baojie

DOI:
[10.33612/diss.124219664](https://doi.org/10.33612/diss.124219664)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
Zhang, B. (2020). *Mechanisms of TRAIL-resistance: novel targets to enhance TRAIL sensitization for cancer therapy*. University of Groningen. <https://doi.org/10.33612/diss.124219664>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Chapter 8

Nederlandse Samenvatting

Bibliography

Acknowledgements

Publications

Nederlandse Samenvatting

TNF-gerelateerd apoptose-inducerend ligand (TRAIL) is in staat om in vitro tumorcellen te doden en gezonde cellen te sparen. Bovendien laten klinische studies zien dat patiënten het recombinant menselijke TRAIL (Dulanermin) goed kunnen verdragen. Al met al, maken de veiligheid van de behandeling en de gerichte apoptose van tumorcellen het oplosbare TRAIL-eiwit tot een veelbelovend geneesmiddel.

TRAIL behoort tot de TNF superfamilie en is het enige cytokine, dat bindt aan twee verschillende celdood receptoren, DR4 en DR5. Binding van TRAIL activeert de vorming van DISC, wat leidt tot caspase-afhankelijke apoptose. Naast het induceren van deze apoptotische signaleringsroute, kan TRAIL de ook de niet-gangbare, interne, kinase route activeren via dezelfde celdood receptoren. Zo kunnen, als voorbeeld, celdood receptoren na binding van TRAIL andere eiwitten aantrekken, om een secundair complex te vormen in plaats van de DISC. Dit multi-eiwitcomplex initieert overlevings- of proliferatie signaleringsroutes. Het vermogen van TRAIL om ook overleving of proliferatie te induceren is een van de redenen waarom tumorcellen resistent kunnen worden tegen TRAIL. Bovendien is de aanwezigheid van celdood receptoren op het plasmamembraan essentieel voor het initiëren van apoptose. Bijvoorbeeld, celdood receptoren in autophagosomen kunnen zich gedragen als lokreceptoren, die binden aan TRAIL om vervolgens autophagie te induceren in borstkankercellen.

In dit proefschrift ontrafelden we moleculaire mechanismen, die de TRAIL-gevoeligheid in tumorcellen controleren, met behulp van DR4- en DR5-specifieke TRAIL-varianten (**hoofdstuk 2 en 3**). Bovendien gebruikten we gecombineerde behandelingen met epigenetische geneesmiddelen om TRAIL-resistentie in tumorcellen te overwinnen (**hoofdstuk 5 en 6**).

Post-translationele modificaties, zoals glycosylering, bleken te correleren met gevoeligheid voor TRAIL. In **hoofdstuk 2** gebruikten we agonistische receptor-specifieke TRAIL-varianten om de individuele bijdrage van elke celdood receptor afzonderlijk, DR4 en DR5, te ontleden. Daartoe is gekeken naar het effect van door FUT3 en FUT6-gemedieerde fucosylering op de activiteit van de afzonderlijke receptoren. We ontdekten dat COLO 205 cellen, die een hoog expressie niveau van FUT3 en FUT6 hebben, gevoelig zijn voor zowel DR4- als DR5-gemedieerde apoptose. DLD-1- en HCT 116 cellen, die een relatief laag expressie level van FUT3 of FUT6 vertonen, zijn echter alleen gevoelig voor DR4-gemedieerde apoptose. Daarom hebben we FUT3-, respectievelijk FUT6-overexpresserende cellijnen gegenereerd en hun gevoeligheid voor de TRAIL-varianten onderzocht. Uit onze gegevens blijkt dat de DR5-gevoeligheid volledig is hersteld in FUT3- of FUT6-overexpresserende cellen.

Verder hebben we onthuld dat fucosylering de vorming van DISC en activering van caspase-8 beïnvloedt. Interessant is ook dat DR5-gemedieerde apoptose wordt verhoogd door extern toevoegen van L-fucose.

Extracellulaire blaasjes (EV's) zijn belangrijk bij intercellulaire communicatie. EV's dragen de boodschappen, waaronder DNA's en eiwitten, van donorcellen en leveren de inhoud af aan de ontvangende cellen. In **hoofdstuk 3** hebben we eerst aangetoond dat geconditioneerd medium (CM) afkomstig van kankercellen, TRAIL-gemedieerde celdood remt. Bovendien hebben we alleen DR5, maar niet DR4 in CM waargenomen. Vervolgens genereerden we cellijnen, die lange of korte varianten van DR5 tot overexpressie brengen en bewezen dat beide varianten bijdragen aan het verminderde aantal apoptotische cellen veroorzaakt door TRAIL. Verder detecteerden we DR5, maar niet DR4 aan het oppervlak van EV's. Tot slot hebben we laten zien dat TRAIL gevoeligheid wordt verbeterd na het weg halen van EV's uit het medium.

Hier boven genoemde twee hoofdstukken bieden nieuwe inzichten in het begrijpen van TRAIL-resistentie fenomenen. Vervolgens richten we ons op het verbeteren van TRAIL-gevoeligheid met combinatie strategieën. Histonen zijn de centrale componenten van nucleosomen. Daarom geven we een overzicht van recente studies over de rol van post-translationele modificaties van histonen in **hoofdstuk 4**. We hebben ook strategieën samengevat voor combinatietherapie om TRAIL gevoeligheid te verbeteren door te interfereren met afwijkende histon modificaties met behulp van remmers.

Histon acetylering is een van de belangrijke modificaties. Dit dynamische proces wordt gereguleerd door histonacetyltransferases (HATs), histondeacetylases (HDACs) en bromodomein eiwitten. In **hoofdstuk 5** gebruikten we eerst verschillende HDAC-remmers om de veranderingen van TRAIL-gevoeligheid op darmkankercellen te onderzoeken. We ontdekten dat RGFP966, een HDAC3-specifieke remmer, of PCI34051, een HDAC8-specifieke remmer, de TRAIL-gevoeligheid grotendeels verbetert in combinatie met agonistische receptor specifieke TRAIL-varianten. Bovendien werden meer apoptotische cellen waargenomen na de behandeling met TRAIL-varianten in HDAC1, 2 of 3 down gereguleerde cellen. Tot slot hebben we bewezen dat RGFP966 en PCI34051 TRAIL-geïnduceerde apoptose ook in 3D-sferoïd modellen verbeteren.

Niet-kleincellig longcarcinooma (NSCLC) is goed voor ongeveer 85% van de gevallen van longkanker. Klinische studies tonen aan dat EGFR-TKIs (EGFR-tyrosine kinase-remmers) efficiënter therapieën zijn dan chemotherapie. Patiënten die behandeld worden met de eerste generatie EGFR-TKI, zoals erlotinib, kunnen echter gemakkelijk resistentie ontwikkelen. In **hoofdstuk 6** hebben we een nieuwe p300 en CBP-selectieve remmer, A485, en TRAIL

gecombineerd om dit probleem op te lossen. We toonden aan dat de A485-TRAIL combinatie synergistisch celdood verhoogt en het volume van 3D-sferoiden van EGFR-TKI resistente cellen vermindert. Verder hebben we bewezen dat A485 TRAIL-geïnduceerde apoptose vergroot via de caspase cascade. Deze verbeterde apoptose is te danken aan het verhogen van genexpressie van caspases, zoals CASP3, 7, 8 en 9. Samengevat, tonen we een succesvolle combinatie van A485 en TRAIL in EGFR-TKI-gevoelige en resistente NSCLC cellen.

Bibliography

1. Galluzzi, L. *et al.* Essential versus accessory aspects of cell death: Recommendations of the NCCD 2015. *Cell Death Differ.* **22**, 58–73 (2015).
2. Tang, D. *et al.* The molecular machinery of regulated cell death. *Cell Res.* **29**, 347–364 (2019).
3. Kerr, J. F. R. Shrinkage Necrosis: A Distinct Mode of Cellular Death. **105**, 13–20 (1971).
4. Ashkenazi, A. Targeting the extrinsic apoptotic pathway in cancer: Lessons learned and future directions. *J. Clin. Invest.* **125**, 487–489 (2015).
5. Boatright, K. M. *et al.* A unified model for apical caspase activation. *Mol. Cell* **11**, 529–541 (2003).
6. Riedl, S. J. *et al.* Molecular mechanisms of caspase regulation during apoptosis. *Nat. Rev. Mol. Cell Biol.* **5**, 897–907 (2004).
7. Tait, S. W. *et al.* Mitochondria and cell death: Outer membrane permeabilization and beyond. *Nat. Rev. Mol. Cell Biol.* **11**, 621–632 (2010).
8. Kuang, A. A. *et al.* FADD is required for DR4- and DR5-mediated apoptosis. Lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts. *J. Biol. Chem.* **275**, 25065–25068 (2000).
9. Kischkel, F. C. *et al.* Apo2L/TRAIL-Dependent Recruitment of Endogenous FADD and Caspase-8 to Death Receptors 4 and 5. *Immunity* **12**, 611–620 (2000).
10. Li, H. *et al.* Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. *Cell* **94**, 491–501 (1998).
11. Schug, Z. T. *et al.* BID is cleaved by caspase-8 within a native complex on the mitochondrial membrane. *Cell Death Differ.* **18**, 538–548 (2011).
12. Özören, N. *et al.* Defining characteristics of types I and II apoptotic cells in response to TRAIL. *Neoplasia* **4**, 551–557 (2002).
13. Herbst, R. S. *et al.* Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. *J. Clin. Oncol.* **28**, 2839–2846 (2010).
14. Van Geelen *et al.* Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: Paving the road to patient-tailored therapy. *Drug Resist. Updat.* **7**, 345–358 (2004).
15. Li, X. *et al.* Reversal of the Apoptotic Resistance of Non-Small-Cell Lung Carcinoma towards TRAIL by Natural Product Toosendanin. *Sci. Rep.* **7**, 1–17 (2017).
16. Shin, E. C. *et al.* Human hepatocellular carcinoma cells resist to TRAIL-induced

- apoptosis, and the resistance is abolished by cisplatin. *Exp. Mol. Med.* **34**, 114–122 (2002).
17. Reis, C. R. *et al.* Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants. **1**, e83-10 (2010).
 18. van der Sloot, A. M. *et al.* Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. *Proc. Natl. Acad. Sci. U. S. A.* **103**, 8634–8639 (2006).
 19. Bray, F. *et al.* Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* **0**, 1–31 (2018).
 20. Siegel, R. L. *et al.* Cancer statistics, 2019 (US statistics). *CA. Cancer J. Clin.* **69**, 7–34 (2019).
 21. Lim, B. *et al.* FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer. *Cancer Biol. Ther.* **14**, 711–719 (2013).
 22. Christiansen, M. N. *et al.* Cell surface protein glycosylation in cancer. *Proteomics* **14**, 525–546 (2014).
 23. Wagner, K. W. *et al.* Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. *Nat. Med.* **13**, 1070–1077 (2007).
 24. Reis, C. R. *et al.* Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants. *Cell Death Dis.* **1**, e83 (2010).
 25. El Andaloussi *et al.* Extracellular vesicles: Biology and emerging therapeutic opportunities. *Nat. Rev. Drug Discov.* **12**, 347–357 (2013).
 26. Han, M. *et al.* Epigenetic enzyme mutations: Role in tumorigenesis and molecular inhibitors. *Front. Oncol.* **9**, (2019).
 27. Lasko, L. M. *et al.* Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. *Nature* **550**, 128–132 (2017).
 28. Bray, F. *et al.* Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* **0**, 1–31 (2018).
 29. Brian M, W. *et al.* Systemic Treatment of Colorectal Cancer. *Gastroenterology* **134**, 1296–1310 (2009).
 30. Chadi, S. A. *et al.* Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. *Lancet Gastroenterol. Hepatol.* **1253**, 1–12 (2018).
 31. Puig, I. *et al.* Accuracy of the Narrow-band Imaging International Colorectal Endoscopic

- Classification System in Identification of Deep Invasion in Colorectal Polyps. *Gastroenterology in press*, (2018).
32. Hall, M. A. *et al.* Clearing the TRAIL for Cancer Therapy. *Cancer Cell* **12**, 4–6 (2007).
 33. Ashkenazi, A. *et al.* Safety and antitumor activity of recombinant soluble Apo2 ligand. *J. Clin. Invest.* **104**, 155–162 (1999).
 34. Lawrence, D. *et al.* Differential hepatocyte toxicity of recombinant Apo2L / TRAIL versions. *Nat. Med.* **364**, 2000–2002 (2001).
 35. Pennarun, B. *et al.* Playing the DISC: Turning on TRAIL death receptor-mediated apoptosis in cancer. *Biochim. Biophys. Acta - Rev. Cancer* **1805**, 123–140 (2010).
 36. LeBlanc, H. N. *et al.* Apo2L/TRAIL and its death and decoy receptors. *Cell Death Differ.* **10**, 66–75 (2003).
 37. Sheridan, J. P. Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors. *Science (80-.)*. **277**, 818–821 (1997).
 38. Kimberley, F. C. *et al.* Following a TRAIL: update on a ligand and its five receptors. *Cell Res.* **14**, 359–372 (2004).
 39. Pan, G. An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL. *Science (80-.)*. **277**, 815–818 (1997).
 40. Marsters, S. A. *et al.* A novel receptor for Apo2L / TRAIL contains a truncated death domain. *Curr. Biol.* **7**, 1003–1006 (1997).
 41. Clancy, L. *et al.* Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 18099–18104 (2005).
 42. Schneider, P. *et al.* TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF- κ B. *Immunity* **7**, 831–836 (1997).
 43. Chaudhary, P. M. *et al.* Death Receptor 5, a New Member of the TNFR Family, and DR4 Induce FADD-Dependent Apoptosis and Activate the NF- κ B Pathway. *Immunity* **7**, 821–830 (1997).
 44. Kuang, A. A. *et al.* FADD is required for DR4- and DR5-mediated apoptosis. Lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts. *J. Biol. Chem.* **275**, 25065–25068 (2000).
 45. Siegmund, D. *et al.* Cell death-independent activities of the death receptors CD95, TRAILR1, and TRAILR2. *FEBS J.* **284**, 1131–1159 (2017).
 46. Bodmer, J. L. *et al.* TRAIL receptor-2 signals apoptosis through FADD and caspase-8. *Nat. Cell Biol.* **2**, 241–243 (2000).

47. Sprick, M. R. *et al.* FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. *Immunity* **12**, 599–609 (2000).
48. Kischkel, F. C. *et al.* Apo2L/TRAIL-Dependent Recruitment of Endogenous FADD and Caspase-8 to Death Receptors 4 and 5. *Immunity* **12**, 611–620 (2000).
49. Salvesen, G. S. *et al.* SnapShot: Caspases. *Cell* **147**, 476-476.e1 (2011).
50. Budihardjo, I. *et al.* Biochemical pathways of caspase activation during apoptosis. *Annu. Rev. Cell Dev. Biol.* **15**, 269–290 (1999).
51. Wagner, K. W. *et al.* Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. *Nat. Med.* **13**, 1070–1077 (2007).
52. Saturno, G. *et al.* Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling. *Oncotarget* **4**, 1185–98 (2013).
53. Kelley, S. K. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. *J. Pharmacol. Exp. Ther.* **299**, 31–38 (2001).
54. Trarbach, T. *et al.* Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. *Br. J. Cancer* **102**, 506–512 (2010).
55. Sirtl, S. *et al.* Hypertonicity-enforced BCL-2 addiction unleashes the cytotoxic potential of death receptors. *Oncogene* **37**, 4122–4136 (2018).
56. Lim, B. *et al.* FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer. *Cancer Biol. Ther.* **14**, 711–719 (2013).
57. Taberero, J. *et al.* Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab. *Target. Oncol.* **10**, 65–76 (2015).
58. Christiansen, M. N. *et al.* Cell surface protein glycosylation in cancer. *Proteomics* **14**, 525–546 (2014).
59. Becker, D. J. *et al.* Fucose: Biosynthesis and biological function in mammals. *Glycobiology* **13**, (2003).
60. Miyoshi, E. *et al.* Biological function of fucosylation in cancer biology. *J. Biochem.* **143**, 725–729 (2008).
61. Haltiwanger, R. S. Fucose is on the TRAIL of colon cancer. *Gastroenterology* **137**, 36–

- 39 (2009).
62. Moriwaki, K. *et al.* Deficiency of GMDS Leads to Escape from NK Cell-Mediated Tumor Surveillance Through Modulation of TRAIL Signaling. *Gastroenterology* **137**, 188–198 (2009).
 63. Moriwaki, K. *et al.* The effect of epigenetic regulation of fucosylation on TRAIL-induced apoptosis. *Glycoconj. J.* **27**, 649–659 (2010).
 64. Dufour, F. *et al.* N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death. *Cell Death Differ.* **24**, 500–510 (2017).
 65. Duiker, E. W. *et al.* Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model. *Clin. Cancer Res.* **15**, 2048–2057 (2009).
 66. Meijer, A. *et al.* Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL. *Br. J. Cancer* **109**, 2685–95 (2013).
 67. Szegezdi, E. *et al.* Kinetics in Signal Transduction Pathways Involving Promiscuous Oligomerizing Receptors Can Be Determined by Receptor Specificity: Apoptosis Induction by TRAIL. *Mol. Cell. Proteomics* **11**, M111.013730 (2012).
 68. Moriwaki, K. *et al.* GDP-mannose-4,6-dehydratase (GMDS) deficiency renders colon cancer cells resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor- and CD95-mediated apoptosis by inhibiting complex II formation. *J. Biol. Chem.* **286**, 43123–43133 (2011).
 69. Burkart, M. D. *et al.* Chemo-enzymatic synthesis of fluorinated sugar nucleotide: Useful mechanistic Probes for glycosyltransferases. *Bioorganic Med. Chem.* **8**, 1937–1946 (2000).
 70. Rillahan, C. D. *et al.* Global Metabolic Inhibitors of Sialyl- and Fucosyltransferases. *Nat. Chem. Biol.* **8**, 661–668 (2012).
 71. Fukumori, F. *et al.* Primary structure of a fucose-specific lectin obtained from a mushroom, *Aleuria aurantia*. *J. Biochem.* **107**, 190–196 (1990).
 72. Wimmerova, M. *et al.* Crystal structure of fungal lectin six-bladed beta-propeller fold and novel fucose recognition mode for *Aleuria aurantia* lectin. *J. Biol. Chem.* **278**, 27059–27067 (2003).
 73. Sessler, T. *et al.* Structural determinants of DISC function: New insights into death receptor-mediated apoptosis signalling. *Pharmacol. Ther.* **140**, 186–199 (2013).
 74. Polanski, R. *et al.* Caspase-8 activation by TRAIL monotherapy predicts responses to IAPi and TRAIL combination treatment in breast cancer cell lines. *Cell Death Dis.* **6**,

- e1893 (2015).
75. Liu, Y.-C. *et al.* Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. *Proc. Natl. Acad. Sci. U. S. A.* **108**, 11332–11337 (2011).
 76. Marquardt, T. *et al.* Correction of leukocyte adhesion deficiency type II with oral fucose. *Blood* **94**, 3976–85 (1999).
 77. Lühn, K. *et al.* Discontinuation of fucose therapy in LADII causes rapid loss of selectin ligands and rise of leukocyte counts. *Blood* **97**, 330–332 (2001).
 78. Tomsik, P. *et al.* L-rhamnose and L-fucose suppress cancer growth in mice. *Cent. Eur. J. Biol.* **6**, 1–9 (2011).
 79. Neumann, S. *et al.* Dominant negative effects of tumor necrosis factor (tnf)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by Formation of heteromeric complexes. *J. Biol. Chem.* **289**, 16576–16587 (2014).
 80. Aoyagi, Y. *et al.* The usefulness of simultaneous determinations of glucosaminylation and fucosylation indices of alpha-fetoprotein in the differential diagnosis of neoplastic diseases of the liver. *Cancer* **67**, 2390–2394 (1991).
 81. Taketa, K. *et al.* A Collaborative Study for the Evaluation of Lectin-Reactive a-Fetoproteins in Early Detection of Hepatocellular Carcinoma. *Cancer Res.* **53**, 5419–5424 (1993).
 82. Kyselova, Z. *et al.* Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. *Clin. Chem.* **54**, 1166–1175 (2008).
 83. Lin, Z. *et al.* Article A Mass Spectrometric Assay for Analysis of Haptoglobin Fucosylation in Pancreatic Cancer A Mass Spectrometric Assay for Analysis of Haptoglobin Fucosylation in Pancreatic Cancer. *J. Proteome Res.* 2602–2611 (2011).
 84. Van Niel *et al.* Shedding light on the cell biology of extracellular vesicles. *Nat. Rev. Mol. Cell Biol.* **19**, 213–228 (2018).
 85. Rivera, J. *et al.* Bacillus anthracis produces membrane-derived vesicles containing biologically active toxins. *Proc. Natl. Acad. Sci. U. S. A.* **107**, 19002–19007 (2010).
 86. Cui, Y. *et al.* Plant extracellular vesicles. *Protoplasma* (2019). doi:10.1007/s00709-019-01435-6
 87. Yáñez-Mó, M. *et al.* Biological properties of extracellular vesicles and their physiological functions. *J. Extracell. Vesicles* **4**, 27066 (2015).
 88. Colombo, M. *et al.* Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles. *Annu. Rev. Cell Dev. Biol.* **30**, 255–289 (2014).

89. Johnstone, R. M. *et al.* Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). *J. Biol. Chem.* **262**, 9412–9420 (1987).
90. McGough, I. J. *et al.* Exosomes in developmental signalling. *Dev.* (2016). doi:10.1242/dev.126516
91. Cocucci, E. *et al.* Shedding microvesicles: artefacts no more. *Trends Cell Biol.* **19**, 43–51 (2009).
92. Wong, S. H. M. *et al.* The TRAIL to cancer therapy: Hindrances and potential solutions. *Crit. Rev. Oncol. Hematol.* **143**, 81–94 (2019).
93. Nagata, S. Apoptosis by death factor. *Cell* **88**, 355–365 (1997).
94. Mahalingam, D. *et al.* TRAIL receptor signalling and modulation: Are we on the right TRAIL? *Cancer Treat. Rev.* **35**, 280–288 (2009).
95. Kojima, Y. *et al.* Importin β 1 protein-mediated nuclear localization of Death Receptor 5 (DR5) limits DR5/Tumor Necrosis Factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cell death of human tumor cells. *J. Biol. Chem.* **286**, 43383–43393 (2011).
96. Di, X. *et al.* Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5. *Oncotarget* **4**, 1349–1364 (2013).
97. Van De Kooij, B. *et al.* Ubiquitination by the membrane-associated RING-CH-8 (MARCH-8) ligase controls steady-state cell surface expression of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) receptor 1. *J. Biol. Chem.* **288**, 6617–6628 (2013).
98. Raposo, G. *et al.* B lymphocytes secrete antigen-presenting vesicles. *J. Exp. Med.* **183**, 1161–1172 (1996).
99. Denzer, K. *et al.* Exosome: From internal vesicle of the multivesicular body to intercellular signaling device. *J. Cell Sci.* **113**, 3365–3374 (2000).
100. Rivoltini, L. *et al.* TNF-related apoptosis-inducing ligand (trail)-armed exosomes deliver proapoptotic signals to tumor site. *Clin. Cancer Res.* **22**, 3499–3512 (2016).
101. Livshits, M. A. *et al.* Isolation of exosomes by differential centrifugation: Theoretical analysis of a commonly used protocol *Scientific Reports* **5**, 17319 (2016).
102. Austin, C. D. *et al.* Death-receptor activation halts clathrin-dependent endocytosis. *Proc. Natl. Acad. Sci. U. S. A.* **103**, 10283–10288 (2006).
103. Kohlhaas, S. L. *et al.* Receptor-mediated endocytosis is not required for TRAIL-induced

- apoptosis. *J. Biol. Chem.* **282**, 12831-12841 (2007).
104. Reis, C. R. *et al.* TRAIL-death receptor endocytosis and apoptosis are selectively regulated by dynamin-1 activation. *Proc. Natl. Acad. Sci. U. S. A.* **114**, 504–509 (2017).
 105. Dawson, M. A. *et al.* Cancer epigenetics: From mechanism to therapy. *Cell* **150**, 12–27 (2012).
 106. Luger, K. *et al.* New insights into nucleosome and chromatin structure: An ordered state or a disordered affair? *Nat. Rev. Mol. Cell Biol.* **13**, 436–447 (2012).
 107. Wong, S. H. M. *et al.* The TRAIL to cancer therapy: Hindrances and potential solutions. *Crit. Rev. Oncol. Hematol.* **143**, 81–94 (2019).
 108. Iberg, A. N. *et al.* Arginine methylation of the histone H3 tail impedes effector binding. *J. Biol. Chem.* **283**, 3006–3010 (2008).
 109. Zhao, Q. *et al.* PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. *Nat. Struct. Mol. Biol.* **16**, 304–311 (2009).
 110. Keller, L. *et al.* JMJD6 Is a Histone Arginine Demethylase. *Science (80-.)*. **318**, 444–447 (2007).
 111. Webby, C. J. *et al.* Jmjd6 Catalyses Lysyl-Hydroxylation of U2AF65, a Protein Associated with RNA Splicing. *Science (80-.)*. **325**, 90–93 (2009).
 112. Hong, X. *et al.* Interaction of JMJD6 with single-stranded RNA. *Proc. Natl. Acad. Sci. U. S. A.* **107**, 14568–14572 (2010).
 113. Mantri, M. *et al.* Crystal structure of the 2-Oxoglutarate- and Fe(II)-dependent lysyl hydroxylase JMJD6. *J. Mol. Biol.* **401**, 211–222 (2010).
 114. Li, S. *et al.* JMJD1B Demethylates H4R3me2s and H3K9me2 to Facilitate Gene Expression for Development of Hematopoietic Stem and Progenitor Cells. *Cell Rep.* **23**, 389–403 (2018).
 115. Hamam, H. J. *et al.* Post-translational modifications in netosis and nets-mediated diseases. *Biomolecules* **9**, 1–25 (2019).
 116. Song, S. *et al.* Progression on citrullination of proteins in gastrointestinal cancers. *Front. Oncol.* **9**, 1–6 (2019).
 117. Kerimoglu, C. *et al.* KMT2A and KMT2B Mediate Memory Function by Affecting Distinct Genomic Regions. *Cell Rep.* **20**, 538–548 (2017).
 118. Hyun, K. *et al.* Writing, erasing and reading histone lysine methylations. *Exp. Mol. Med.* **49**, (2017).
 119. Shi, Y. *et al.* The discovery of histone demethylases. *Cold Spring Harb. Perspect. Biol.*

- 5, 2–4 (2013).
120. Chen, Y. *et al.* Lysine propionylation and butyrylation are novel post-translational modifications in histones. *Mol. Cell. Proteomics* **6**, 812–819 (2007).
 121. Dai, L. *et al.* Lysine 2-hydroxyisobutyrylation is a widely distributed active histone mark. *Nat. Chem. Biol.* **10**, 365–370 (2014).
 122. Tan, M. *et al.* Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. *Cell* **146**, 1016–1028 (2011).
 123. Xie, Z. *et al.* Lysine succinylation and lysine malonylation in histones. *Mol. Cell. Proteomics* **11**, 100–107 (2012).
 124. Jeusset, L. *et al.* Developing Targeted Therapies That Exploit Aberrant Histone Ubiquitination in Cancer. *Cells* **8**, 165 (2019).
 125. Cubeñas-Potts, C. *et al.* SUMO: A Multifaceted Modifier of Chromatin Structure and Function. *Dev. Cell* **24**, 1–12 (2013).
 126. Rossetto, D. *et al.* Histone phosphorylation. *Epigenetics* **7**, 1098–1108 (2012).
 127. Yang, Y. *et al.* Protein arginine methyltransferases and cancer. *Nat. Rev. Cancer* **13**, 37–50 (2013).
 128. Pal, S. *et al.* Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma. *EMBO J.* **26**, 3558–3569 (2007).
 129. Chung, J. *et al.* Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) Silencing. *J. Biol. Chem.* **288**, 35534–35547 (2013).
 130. Zhu, F. *et al.* PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells. *Leukemia* **33**, 2898–2911 (2019).
 131. Chung, J. *et al.* Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT/ β -catenin and AKT/GSK3 β proliferative signaling. *J. Biol. Chem.* **294**, 7692–7710 (2019).
 132. Alinari, L. *et al.* Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation. *Blood* **125**, 2530–2543 (2015).
 133. Kim, Y. R. *et al.* Differential CARM1 expression in prostate and colorectal cancers. *BMC Cancer* **10**, 1–13 (2010).
 134. Takahashi, Y. *et al.* Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive lesions of primary breast cancer. *Breast Cancer* **19**, 242–252 (2012).
 135. Zhong, J. *et al.* Identification and characterization of novel spliced variants of PRMT2

- in breast carcinoma. *FEBS J.* **279**, 316–335 (2012).
136. Yoshimatsu, M. *et al.* Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. *Int. J. Cancer* **128**, 562–573 (2011).
 137. Cheung, N. *et al.* Protein arginine-methyltransferase-dependent oncogenesis. *Nat. Cell Biol.* **9**, 1208–1215 (2007).
 138. Fedoriw, A. *et al.* Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss. *Cancer Cell* **36**, 100-114.e25 (2019).
 139. Husmann, D. *et al.* Histone lysine methyltransferases in biology and disease. *Nat. Struct. Mol. Biol.* **26**, 880–889 (2019).
 140. Arrowsmith, C. H. *et al.* Epigenetic protein families: A new frontier for drug discovery. *Nat. Rev. Drug Discov.* **11**, 384–400 (2012).
 141. Kuzmichev, A. *et al.* Histone methyltransferase activity of Zeste protein complex containing the Enhancer associated with a human multiprotein. *Genes Dev.* **16**, 2893–905 (2002).
 142. Li, B. *et al.* EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications. *J. Hematol. Oncol.* **12**, 118 (2019).
 143. Lue, J. K. *et al.* Emerging EZH2 Inhibitors and Their Application in Lymphoma. *Curr. Hematol. Malig. Rep.* **13**, 369–382 (2018).
 144. McCabe, M. T. *et al.* Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). *Proc. Natl. Acad. Sci. U. S. A.* **109**, 2989–2994 (2012).
 145. Mann, B. S. *et al.* FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma. *Oncologist* **12**, 1247–1252 (2007).
 146. Lee, H. Z. *et al.* FDA approval: Belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. *Clin. Cancer Res.* **21**, 2666–2670 (2015).
 147. Raedler, L. A. Farydak (Panobinostat): First HDAC Inhibitor Approved for Patients with Relapsed Multiple Myeloma. *Am. Heal. drug benefits* **9**, 84–87 (2016).
 148. Santo, L. *et al.* Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. *Blood* **119**, 2579–2589 (2012).
 149. Cosenza, M. *et al.* Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine. *Apoptosis* **22**, 827–840 (2017).

150. Vogl, D. T. *et al.* Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. *Clin. Cancer Res.* **23**, 3307–3315 (2017).
151. Bowers, E. M. *et al.* Virtual ligand screening of the p300/CBP histone acetyltransferase: Identification of a selective small molecule inhibitor. *Chem. Biol.* **17**, 471–482 (2010).
152. Dahlin, J. L. *et al.* Assay interference and off-target liabilities of reported histone acetyltransferase inhibitors. *Nat. Commun.* **8**, 1–14 (2017).
153. Wang, R. *et al.* Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP. *Mol. Cancer Ther.* **17**, 2543–2550 (2018).
154. Lasko, L. M. *et al.* Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. *Nature* **550**, 128–132 (2017).
155. Rathore, R. *et al.* Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs). *Apoptosis* **22**, 898–919 (2017).
156. Von Karstedt, S. *et al.* Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. *Nat. Rev. Cancer* **17**, 352–366 (2017).
157. Croft, M. *et al.* Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases. *Nat. Rev. Rheumatol.* **13**, 217–233 (2017).
158. Woo, S. M. *et al.* BIX-01294 sensitizes renal cancer Caki cells to TRAIL-induced apoptosis through downregulation of survivin expression and upregulation of DR5 expression. *Cell Death Discov.* **4**, (2018).
159. Kim, S. Y. *et al.* Inhibition of euchromatin histone-lysine N-methyltransferase 2 sensitizes breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through reactive oxygen species-mediated activating transcription factor 4-C/EBP homologous protein-de. *Mol. Carcinog.* **57**, 1492–1506 (2018).
160. Kurt, I. C. *et al.* KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL. *Cell Death Dis.* **8**, e2897 (2017).
161. Tanaka, H. *et al.* PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor- κ B activation. *Mol. Cancer Res.* **7**, 557–569 (2009).
162. Kauh, J. *et al.* C-FLIP degradation mediates sensitization of pancreatic cancer cells to trail-induced apoptosis by the histone deacetylase inhibitor LBH589. *PLoS One* **5**, (2010).
163. Symanowski, J. *et al.* A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL. *J. Thorac. Oncol.* **4**, 149–160 (2009).

164. Zhao, L. *et al.* Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma. *Neoplasia (United States)* **21**, 82–92 (2019).
165. Kerr, E. *et al.* Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis. *Cell Death Differ.* **19**, 1317–1327 (2012).
166. Minami, J. *et al.* Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. *Leukemia* **28**, 680–689 (2014).
167. Tang, S. *et al.* Histone deacetylase inhibitor BG45-mediated HO-1 expression induces apoptosis of multiple myeloma cells by the JAK2/STAT3 pathway. *Anticancer. Drugs* **29**, 61–74 (2018).
168. Harada, T. *et al.* HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications. *Leukemia* **31**, 2670–2677 (2017).
169. Guerriero, J. L. *et al.* Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. *Nature* **543**, 428–432 (2017).
170. Marek, L. *et al.* Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. *J. Med. Chem.* **56**, 427–436 (2013).
171. Li, X. *et al.* Histone deacetylase inhibitor LMK-235-mediated HO-1 expression induces apoptosis in multiple myeloma cells via the JNK/AP-1 signaling pathway. *Life Sci.* **223**, 146–157 (2019).
172. Wanek, J. *et al.* Pharmacological inhibition of class IIA HDACs by LMK-235 in pancreatic neuroendocrine tumor cells. *Int. J. Mol. Sci.* **19**, (2018).
173. Gradilone, S. A. *et al.* HDAC6 inhibition restores ciliary expression and decreases tumor growth. *Cancer Res.* **73**, 2259–2270 (2013).
174. Woan, K. V. *et al.* Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. *Mol. Oncol.* **9**, 1447–1457 (2015).
175. Wang, F. *et al.* SKLB-23bb, A HDAC6-Selective inhibitor, exhibits superior and broad-spectrum antitumor activity via additionally targeting microtubules. *Mol. Cancer Ther.* **17**, 763–775 (2018).
176. Ma, X. *et al.* HDAC-selective Inhibitor Cay10603 Has Single Anti-tumour Effect in Burkitt's Lymphoma Cells by Impeding the Cell Cycle. *Curr. Med. Sci.* **39**, 228–236 (2019).

177. Wang, Z. *et al.* HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma. *Oncol. Rep.* **36**, 589–597 (2016).
178. Bergman, J. A. *et al.* Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. *J. Med. Chem.* **55**, 9891–9899 (2012).
179. Wu, H. *et al.* Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity. *J. Med. Chem.* **62**, 7042–7057 (2019).
180. Sun, X. *et al.* The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma. *Biosci. Rep.* **39**, 1–11 (2019).
181. Rettig, I. *et al.* Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation. *Cell Death Dis.* **6**, 1–14 (2015).
182. Balasubramanian, S. *et al.* A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. *Leukemia* **22**, 1026–1034 (2008).
183. Lopez, G. *et al.* HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST). *PLoS One* **10**, 1–12 (2015).
184. Wang, R. *et al.* Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP. *Mol. Cancer Ther.* **17**, 2543–2550 (2018).
185. Benoit, Y. D. *et al.* Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells. *J. Cell. Physiol.* **228**, 764–772 (2013).
186. Kasman, L. *et al.* Histone Deacetylase Inhibitors Restore Cell Surface Expression of the Coxsackie Adenovirus Receptor and Enhance CMV Promoter Activity in Castration-Resistant Prostate Cancer Cells. *Prostate Cancer* **2012**, 1–8 (2012).
187. Srivastava, R. K. *et al.* MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. *Mol. Cancer Ther.* **9**, 3254–3266 (2010).
188. Borbone, E. *et al.* Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. *Oncogene* **29**, 105–116 (2010).
189. Nebbioso, A. *et al.* C-Myc modulation and acetylation is a key HDAC inhibitor target in cancer. *Clin. Cancer Res.* **23**, 2542–2555 (2017).
190. Zhang, B. *et al.* Histone deacetylase inhibitors sensitize TRAIL-induced apoptosis in

- colon cancer cells. *Cancers (Basel)*. **11**, (2019).
191. Ashkenazi, A. *et al.* Death Receptors: Signaling and Modulation. *Science (80-.)*. **281**, 1305–1308 (1998).
 192. Green, D. R. Apoptotic pathways: Paper wraps stone blunts scissors. *Cell* **102**, 1–4 (2000).
 193. Herbst, R. S. *et al.* Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. *J. Clin. Oncol.* **28**, 2839–2846 (2010).
 194. You, J. S. *et al.*. Cancer Genetics and Epigenetics: Two Sides of the Same Coin? *Cancer Cell* **22**, 9–20 (2012).
 195. Jostes, S. *et al.* Epigenetic drugs and their molecular targets in testicular germ cell tumours. *Nat. Rev. Urol.* **16**, 245–259 (2019).
 196. Baylin, S. B. *et al.* A decade of exploring the cancer epigenome — biological and translational implications. *Nat. Rev. Cancer* **11**, 726–734 (2011).
 197. Dawson, M. A. *et al.* Cancer epigenetics: From mechanism to therapy. *Cell* **150**, 12–27 (2012).
 198. Zhu, P. *et al.* Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. *Cancer Cell* **5**, 455–463 (2004).
 199. Spurling, C. C. *et al.* HDAC3 Overexpression and Colon Cancer Cell Proliferation and Differentiation. *Mol. Carcinog.* **47**, 137–147 (2008).
 200. Boix-Chornet, M. *et al.* A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. *Nat. Genet.* **38**, 566–569 (2006).
 201. Delhanty, J. D. A. *et al.* Mutations truncating the EP300 acetylase in human cancers. *Nat. Genet.* **24**, 300–303 (2000).
 202. Kishimoto, M. *et al.* Mutations and deletions of the CBP gene in human lung cancer. *Clin. Cancer Res.* **11**, 512–519 (2005).
 203. Yang, X. J. *et al.* The Rpd3/Hda1 family of lysine deacetylases: From bacteria and yeast to mice and men. *Nat. Rev. Mol. Cell Biol.* **9**, 206–218 (2008).
 204. Shirakawa, K. *et al.* Reactivation of latent HIV by histone deacetylase inhibitors. *Trends Microbiol.* **21**, 277–285 (2013).
 205. Dorff, S. *et al.* FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma. *Clin. Cancer Res.* **21**, 2666–2670 (2015).
 206. Grant, C. *et al.* Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. *Expert Rev. Anticancer Ther.* **10**, 997–1008 (2010).

207. Pazdur, R. *et al.* FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma. *Oncologist* **12**, 1247–1252 (2007).
208. De Graeff, P. *et al.* EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma. *Oncologist* **23**, 631–636 (2017).
209. Shah, J. J. *et al.* Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. *Blood* **126**, 187 LP – 187 (2015).
210. Shah, R. R. Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology. *Drug Saf.* **42**, 235-245 (2019).
211. McLeod, A. B. *et al.* Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer. *Prostate* **78**, 266–277 (2018).
212. Ramos, J. *et al.* A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. *Leukemia* **22**, 1026–1034 (2008).
213. Aldana-masangkay, G. I. *et al.* Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells. *Leuk lymphoma* **52**, 1544–1555 (2014).
214. Carlisi, D. *et al.* The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. *Eur. J. Cancer* **45**, 2425–2438 (2009).
215. Quast, S. A. *et al.* Sensitization of Melanoma Cells for Death Ligand TRAIL Is Based on Cell Cycle Arrest, ROS Production, and Activation of Proapoptotic Bcl-2 Proteins. *J. Invest. Dermatol.* **135**, 2794–2804 (2015).
216. Saturno, G. *et al.* Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling. *Oncotarget* **4**, 1185–98 (2013).
217. Fulda, S. Histone deacetylase (HDAC) inhibitors and regulation of TRAIL-induced apoptosis. *Exp. Cell Res.* **318**, 1208–1212 (2012).
218. Haecker, S *et al.* Histone deacetylase inhibitors overcome resistance of caspase-8 negative cancers to TRAIL-induced apoptosis by upregulating caspase-8. in *Cancer Research* **67**, 702 (2007).
219. Riley, J. S. *et al.* Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer. *Cell Death Dis.* **4**, e951 (2013).
220. Lauricella, M. *et al.* SAHA/TRAIL combination induces detachment and anoikis of

- MDA-MB231 and MCF-7 breast cancer cells. *Biochimie* **94**, 287–299 (2012).
221. Hektoen, M. *et al.* Epigenetic and genetic features of 24 colon cancer cell lines. *Oncogenesis* **2**, e71–e71 (2013).
 222. Verdin, E. *et al.* 50 years of protein acetylation: From gene regulation to epigenetics, metabolism and beyond. *Nat. Rev. Mol. Cell Biol.* **16**, 258–264 (2015).
 223. Irvine, R. A. *et al.* DNA Methylation Has a Local Effect on Transcription and Histone Acetylation. *Mol. Cell. Biol.* **22**, 6689–6696 (2002).
 224. Micheau, O. Regulation of TNF-related apoptosis-inducing ligand signaling by glycosylation. *Int. J. Mol. Sci.* **19**, (2018).
 225. Zhang, B. *et al.* Death receptor 5 is activated by fucosylation in colon cancer cells. *FEBS J.* **286**, 555–571 (2019).
 226. Montgomery, M. R. *et al.* Alterations in the glycome after HDAC inhibition impact oncogenic potential in epigenetically plastic SW13 cells. *BMC Cancer* **19**, 1–18 (2019).
 227. Allfrey, V. G. *et al.* Acetylation and Methylation of Histones and Their Possible Role in the. *Proc. Natl. Acad. Sci. United States* **51**, 786–794 (1964).
 228. Kouzarides, T. Chromatin Modifications and Their Function. *Cell* **128**, 693–705 (2007).
 229. Patel, J. H. *et al.* The c-MYC Oncoprotein Is a Substrate of the Acetyltransferases hGCN5/PCAF and TIP60. *Mol. Cell. Biol.* **24**, 10826–10834 (2004).
 230. Ghizzoni, M. *et al.* Histone acetyltransferases are crucial regulators in NF- κ B mediated inflammation. *Drug Discov. Today* **16**, 504–511 (2011).
 231. Wapenaar, H. *et al.* Histone acetyltransferases: challenges in targeting bi-substrate enzymes. *Clin. Epigenetics* **8**, 1–11 (2016).
 232. Fiorentino, F. *et al.* Lysine acetyltransferase inhibitors: Structure-activity relationships and potential therapeutic implications. *Future Med. Chem.* **10**, 1067–1091 (2018).
 233. Grossman, S. R. p300/CBP/p53 interaction and regulation of the p53 response. *Eur. J. Biochem.* **268**, 2773–2778 (2001).
 234. Sato, S. *et al.* CBP/p300 as a co-factor for the Microphthalmia transcription factor. *Oncogene* **14**, 3083–3092 (1997).
 235. Munshi, N. *et al.* Acetylation of HMG I(Y) by CBP turns off IFN β expression by disrupting the enhanceosome. *Mol. Cell* **2**, 457–467 (1998).
 236. Merika, M. *et al.* Recruitment of CBP/p300 by the IFN β enhanceosome is required for synergistic activation of transcription. *Mol. Cell* **1**, 277–287 (1998).
 237. Kaypee, S. *et al.* Aberrant lysine acetylation in tumorigenesis: Implications in the development of therapeutics. *Pharmacol. Ther.* **162**, 98–119 (2016).

238. Iyer, N. G *et al.* p300/CBP and cancer. *Oncogene* **23**, 4225–4231 (2004).
239. Yokomizo, C. *et al.* High expression of p300 in HCC predicts shortened overall survival in association with enhanced epithelial mesenchymal transition of HCC cells. *Cancer Lett.* **310**, 140–147 (2011).
240. Ishihama, K. *et al.* Expression of HDAC1 and CBP/p300 in human colorectal carcinomas. *J. Clin. Pathol.* **60**, 1205–1210 (2007).
241. Tang, Z. *et al.* CREB-binding protein regulates lung cancer growth by targeting MAPK and CPSF4 signaling pathway. *Mol. Oncol.* **10**, 317–329 (2016).
242. Lau, O. D. *et al.* HATs off: Selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. *Mol. Cell* **5**, 589–595 (2000).
243. Li, F. *et al.* Garcinol, a polyisoprenylated benzophenone modulates multiple proinflammatory signaling cascades leading to the suppression of growth and survival of head and neck carcinoma. *Cancer Prev. Res.* **6**, 843–854 (2013).
244. Choi, K. C. *et al.* Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation. *Cancer Res.* **69**, 583–592 (2009).
245. Balasubramanyam, K. *et al.* Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. *J. Biol. Chem.* **279**, 51163–51171 (2004).
246. Bowers, E. M. *et al.* Virtual ligand screening of the p300/CBP histone acetyltransferase: Identification of a selective small molecule inhibitor. *Chem. Biol.* **17**, 471–482 (2010).
247. Van Den Bosch, T. *et al.* The histone acetyltransferase p300 inhibitor C646 reduces pro-inflammatory gene expression and inhibits histone deacetylases. *Biochem. Pharmacol.* **102**, 130–140 (2016).
248. Dahlin, J. L. *et al.* Assay interference and off-target liabilities of reported histone acetyltransferase inhibitors. *Nat. Commun.* **8**, 1–14 (2017).
249. Saber, A. *et al.* Genomic aberrations guiding treatment of non-small cell lung cancer patients. *Cancer Treat. Commun.* **4**, 23–33 (2015).
250. Siegelin, M. D. *et al.* Epidermal growth factor receptor mutations in lung adenocarcinoma. *Lab. Invest.* **7**, 169–181 (2007).
251. Rosell, R. *et al.* Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. *Lancet Oncol.* **13**, 239–

- 246 (2012).
252. Wu, Y. L. *et al.* Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial. *Lancet Oncol.* **15**, 213–222 (2014).
 253. Jackman, D. *et al.* Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. *J. Clin. Oncol.* **28**, 357–360 (2010).
 254. Morgillo, F. *et al.* Mechanisms of resistance to EGFR-targeted drugs: Lung cancer. *ESMO Open* **1**, 1–9 (2016).
 255. Hou, X. *et al.* P300 Promotes Proliferation, Migration, and Invasion Via Inducing Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer Cells. *BMC Cancer* **18**, 1–8 (2018).
 256. Liu, B. *et al.* CX chemokine receptor 7 contributes to survival of KRAS-mutant non-small cell lung cancer upon loss of epidermal growth factor receptor. *Cancers (Basel)*. **11**, 1–18 (2019).
 257. Xu, H. *et al.* SRC and MEK co-inhibition synergistically enhances the anti-tumor effect in both Non-Small Cell Lung Cancer (NSCLC) and erlotinib-resistant NSCLC. *Front. Oncol.* **9**, 1–11 (2019).
 258. Zhou, C. *et al.* Strategies to improve outcomes of patients with EGRF-Mutant Non-Small cell lung cancer: Review of the literature. *J. Thorac. Oncol.* **11**, 174–186 (2016).
 259. Hamamoto, J. *et al.* Non-small cell lung cancer PC-9 cells exhibit increased sensitivity to gemcitabine and vinorelbine upon acquiring resistance to EGFR-tyrosine kinase inhibitors. *Oncol. Lett.* **14**, 3559–3565 (2017).
 260. Liu, B. *et al.* Transcriptional activation of cyclin D1 via HER2/HER3 contributes to cell survival and EGFR tyrosine kinase inhibitor resistance in non-small cell lung carcinoma. *bioRxiv* 851279 (2019).
 261. Wimmer, K. *et al.* Circulating biomarkers of cell death. *Clin. Chim. Acta* **500**, 87-97 (2019).
 262. Chou, T. C. Drug combination studies and their synergy quantification using the choutalalay method. *Cancer Res.* **70**, 440–446 (2010).
 263. Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. *Pharmacol. Rev.* **58**, 621–681 (2006).

264. Geiger, K. *et al.* FOXO3/FKHRL1 is activated by 5-aza-2-deoxycytidine and induces silenced caspase-8 in neuroblastoma. *Mol. Biol. Cell* **23**, 2226–2234 (2012).
265. Kaminsky, V. O. *et al.* Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL. *Carcinogenesis* **32**, 1450–1458 (2011).
266. Solassol, I. *et al.* FDA- and EMA-approved tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer: Safety, tolerability, plasma concentration monitoring, and management. *Biomolecules* **9**, e668 (2019).
267. Del Re, M. *et al.* Incidence of T790M in NSCLC patients progressed to gefitinib, erlotinib and afatinib: a study on circulating tumor DNA. *Clin. Lung Cancer* in press (2019).
268. Zhang, B. *et al.* Histone deacetylase inhibitors sensitize TRAIL-induced apoptosis in colon cancer cells. *Cancers (Basel)*. **11**, 1–15 (2019).
269. Van Der Sloot, A. M. *et al.* Stabilization of TRAIL, an all- β -sheet multimeric protein, using computational redesign. *Protein Eng. Des. Sel.* **17**, 673–680 (2004).
270. Chen, W. *et al.* High-throughput image analysis of tumor spheroids: A user-friendly software application to measure the size of spheroids automatically and accurately. *J. Vis. Exp.* **8**, 1–10 (2014).
271. Azijli, K. *et al.* Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family. *Cell Death Differ.* **20**, 858–868 (2013).
272. Di, X. *et al.* Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5. *Oncotarget* **4**, 1349–1364 (2013).
273. Fulton, M. D. *et al.* Mechanisms and Inhibitors of Histone Arginine Methylation. *Chem. Rec.* **18**, 1792–1807 (2018).
274. Di Lorenzo, A. *et al.* Histone arginine methylation. *FEBS Lett.* **585**, 2024–2031 (2011).
275. Article, R. Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers *Adv Biomed Res.* **8** 63 (2019).
276. Audia, J. E. *et al.* Histone modifications and cancer. *Cold Spring Harb. Perspect. Biol.* **8**, (2016).
277. Kebede, A. F. *et al.* Histone propionylation is a mark of active chromatin. *Nat. Struct. Mol. Biol.* **24**, 1048–1056 (2017).
278. Goudarzi, A. *et al.* Dynamic Competing Histone H4 K5K8 Acetylation and Butyrylation Are Hallmarks of Highly Active Gene Promoters. *Mol. Cell* **62**, 169–180 (2016).

279. Ishiguro, T. *et al.* Malonylation of histone H2A at lysine 119 inhibits Bub1-dependent H2A phosphorylation and chromosomal localization of shugoshin proteins. *Sci. Rep.* **8**, 1–10 (2018).
280. Wang, Y. *et al.* KAT2A coupled with the α -KGDH complex acts as a histone H3 succinyltransferase. *Nature* **552**, 273–277 (2017).
281. Stein, E. M. *et al.* The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. *Blood* **131**, 2662–2669 (2018).
282. Waters, N. J. *et al.* Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target. *J. Control. Release* **220**, 758–765 (2015).
283. Waters, N. J. Preclinical Pharmacokinetics and Pharmacodynamics of Pinometostat (EPZ-5676), a First-in-Class, Small Molecule S-Adenosyl Methionine Competitive Inhibitor of DOT1L. *Eur. J. Drug Metab. Pharmacokinet.* **42**, 891–901 (2017).
284. Campbell, C. T. *et al.* Mechanisms of pinometostat (EPZ-5676) treatment–emergent resistance in MLL-rearranged leukemia. *Mol. Cancer Ther.* **16**, 1669–1679 (2017).
285. Blum, K. A. *et al.* 410A phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma. *Ann. Oncol.* **29**, 2018 (2018).
286. Wu, T. *et al.* JNJ-64619178, a selective and pseudo-irreversible PRMT5 inhibitor with potent in vitro and in vivo activity, demonstrated in several lung cancer models. in *Proceedings of the American Association for Cancer Research Annual Meeting 2018*; (2018).
287. Italiano, A. *et al.* Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. *Lancet Oncol.* **19**, 649–659 (2018).
288. Knutson, S. K. *et al.* Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. *Mol. Cancer Ther.* **13**, 842–854 (2014).
289. Brach, D. *et al.* EZH2 inhibition by tazemetostat results in altered dependency on B-cell activation signaling in DLBCL. *Mol. Cancer Ther.* **16**, 2586–2597 (2017).
290. Kurmasheva, R. T. *et al.* Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program. *Pediatr. Blood Cancer* **64**, (2017).
291. Bauer, T. M. *et al.* Phase I, Open-Label, Dose-Escalation Study of the Safety,

- Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC. *J. Thorac. Oncol.* **14**, 1828–1838 (2019).
292. Mohammad, H. P. *et al.* A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. *Cancer Cell* **28**, 57–69 (2015).
293. Rasco, D. *et al.* A phase I, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of GSK3326595 in subjects with solid tumors and non-Hodgkin's lymphoma. (2017).
294. Siu, L. L. *et al.* A Phase I Study of GSK3326595, a First-In-Class Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Advanced Solid Tumors. (2019).
295. Gerhart, S. V. *et al.* Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing. *Sci. Rep.* **8**, 1–15 (2018).

Acknowledgements

Five years past and I still vividly remembered the day I arrived at Schiphol Airport. It was a cold morning. The sky was crystal blue and some clouds were floating. Wide farms were boundless plain and my sight seemed to reach the end of the land. This view reminded me a painting called “Plain near Auvers” drew by a Dutch painter Vincent van Gogh. It was a challenging to study and live in a foreign country and I was worried about my adventure in Groningen. Now, I must say that I enjoyed my life in Groningen and thank you all for accomplishing this wonderful adventure with me!

First of all, I would like to thank my supervisor **Prof. dr. Wim. J. Quax** for offering me this great opportunity to study and work in the University of Groningen. I can never finish my thesis without your support and help. I received very warm welcome from you the first day I came to the lab. During these years, I enjoyed the discussion about projects in our monthly meeting and I also like the personal talking after the meeting. Besides guiding me to finish projects, you also shows good examples in teamwork, leadership and social activities. These wisdom I learned from you will be benefit for my future life. Thank you for everything!

I also want to thank **Prof. dr. Frank J. Dekker**. I have learned many scientific writing skills from you. Your precise and cautious attitude to work influence me a lot. When I was puzzled, you always response quickly and willing to help me. Besides work, we exchanged a lot of experiences in parenting children. It is amazed for me that you and your wife can make 4 children to get ready for school in the morning in only one hour! I wish you and your families have a joyful life and all the best!

Prof. dr. Gerrit J. Poelarends. You are an intelligent gentleman in my eyes. When I link your accomplishments, e.g. winning VENI, VIDI, VICI grants, and the way you work, I feel very lucky to learn a lot from you. For instance, asking questions in seminars is a great way to keep alert and concentrate. Thank you for your suggestions in seminars and being one of my referees. **Prof. dr. Hidde J. Haisma**. I like your voice and the way you speak English. Your sound is always calm and gentle. I enjoyed your presentations a lot because you can always make an interesting story. Thank you for your contributions in our projects.

Dear **Rita**, how lucky I am to meet you in my life. You are amazing and lovely. I have never met anyone who is more generous and helpful than you before. During the work, you taught me the practical skills and helped me to finish my projects. In my personal life, we share a lot of experiences and emotions. Your honesty to yourself and others encourages me to find

my own way. Thank you very much for taking care of me these years and you are always welcome to my home in China!

Dear **Robbert**, thank you for many help with purifying TRAIL and your advices for my projects. You are funny and active. I did not know that “scientific guy” can also sing and dance so well. Wish you happy every day! Dear **Ronald**, thank you for helping me with ordering and arranging things. Every time I came to you for help, you always response quickly and work efficiently. I feel happy to work with you together. By the way, I love your recipe of tapenade. Wish you young forever! Dear **Pieter**, thank you for your hard work and bringing a lot laugh to the lab! Wish you all the best!

My lovely officemates, **Magda, Yizhou and Abel**. We have been through a lot of up and downs these years. We share our joys and sorrows together. It is really delight to meet all of you and I feel very sad to say goodbye to you. Hopefully that we can meet each other again! **Magda**, you are so nice and easy-going. The cakes you made are always the best! I wish you have a wonderful new life in Poland. **Yizhou**, you are very sweet and thoughtful. You look like a little girl but you are actually independent and mature. You are always taking care of others. I have no doubt that you will have a bright future. Wish everything goes as what you want. **Abel**, you are very charming and friendly. You are very smart but you never show it off. You brought so much fun and everyone likes you. I wish your projects will go smoothly so you can finish your PhD on time.

My beautiful girls, **Yafeng, Xinyu, Siqi, Fengzhi**. Thank you for coming to our lab and bringing energy and joy to my life. You are different but you are all very good at cooking. I miss the time we sit together and chat. I wish you all enjoy your life in Groningen and have a bright future!

My coauthors, **Deng and Bin**. You two are workaholic. You both work efficiently and think fast. I enjoy our collaboration and I learned a lot from you. **Deng**, I wish you will get “cum laude” after 4 years. **Bin**, I wish you a great success in your academic career!

My old friend, **Jielin**. What a wonderful coincidence that we did our PhD in the same group after finishing our master study in the same lab! We witness each other’s growing these years and we share a lot. It seems that you are always by my side no matter where you are. I believe that you can conquer every difficulties you meet in your life. Wish you and your families all the best! Little painter **Su**. You are very nice and funny. You are clear about what you want and always go for it. Thank you for your nice painting of our cat “Doudou” and delicious food. Wish your life with Naqin and Duran is full of happiness and sunshine! Sweet **Putri**. You are very social and kind. I always feel cozy when you are around. You are creative and you always

have new ideas. Thank you for inviting me to your wedding and other memorable moments we spent together. Wish you and Johannes a happy and fruitful life! Dear **Shanshan**. You are rational and friendly. No matter when I ask you for a favor, you never say no. Your famous “Chinese hamburg” is very delicious and popular in Groningen. I wish you and Zhangping have a wonderful life together! Lovely **Li Jing**. You are a special and active girl. You are always being yourself. You can always find interesting activities. I am always inspired by your new ideas and insights. Good luck and best wishes to you and your family! Dear **Nadia**. You are very social and confident. When I think of you, I always recall your big smile and “This is a free country”. I miss the time that we talked and laughed together. Wish you are success with everything you want and keep contact!

My previous and current colleagues, **Ingrid, Christel, Ingy, Zheng, Jan, Joko, Hegar, Tjie Kok, Dan, Jan-Ytzen, Yufeng, Harsh, Mehran, Martijn, Laura, Guo Hao, Haigen, Ni Yan, Lieuwe, Guangcai, Fangyuan, Olivia, Marie, Saif, Faizan, Zhangping, Alex, Andreas, Fabiola, Michele, Saravanan, Zainal, Eleonora, Siwei, Roberta, Guo Chao, Linda, Hannah**. Thank you for creating a friendly atmosphere in the lab. Thank you for sharing your projects and all your help. Wish you all the best!

I also meet many lovely people in Groningen. **Jiaying&Jing, Yuanyuan&Liqiang, Tiantian&Siqi, Yifei&Yihui, Yuequ&Cheng**. I am very lucky to meet you guys and your adorable children: Milan, Youran, Xiaoman, Mige and Anna. We share our experiences of raising children and feelings of being a mom. I am also happy for Loui that he had great time with your little ones. I wish nothing but the best for you and your families! Dear **Ironna and Outi**. I am very happy to meet you two and your lovely daughters, Iro and Hilda. Thank you for sharing parenting experiences and supporting me. Maybe it is difficult to meet you after I leave the Netherlands, but I will never forget the time we were together. Ironna, success with your PhD thesis writing. Outi, good luck with everything as you move back to Finland. My neighbor **Peter**. You are nice and cool. Thank you for bearing the noise Loui makes every day. And thank you for your kind help when we were in trouble. Tons of best wishes to you! I am truly thankful to many talent people I met here: **Huatang, Zhenchen, Jingjing, Yuanze, Duan Cong, Xiaoyin, Gaowa, Yana, Huala, Meichen, Lanlin, Hu Xu, Hongyan, Xiaohong, Yuzhen, Shi Ming, Tian Yu, Zhou Lin, Wenjia, Keni, Wenxuan, Xiaoxuan**. It was a lot of fun to be with you guys.

Last but not the least, I want to express my gratitude to my families. Dear **mom and dad**. Thank you very much for supporting me to come to the Netherlands and helping me with raising Loui. I can never finish my PhD without you. I finally understand how much difficulties and

worries you must deal with to raise me up. I love you and now it is my turn to take care of you two. My dear **mother-in law and father-in law**. Thank you for your supporting and caring these years. Especially my mother-in law, thank you for flying 3 times from China to the Netherlands. It took a lot of energy and I really appreciate that. My big boy **Xiaodong**. You are not only good at science but also a sweet husband. You let me see more possibilities of myself and you bring a lot of fun into our life. My heart is singing a chorus when being with you. I am very looking forward to our new stage in life. My little boy **Loui**. You make my life happier than I never thought I could be. It is amazingly wonderful to watch you growing every day. I love you so much and I try my best to learn how to be a great mom.

Love,
Baojie

Publications

[1] **Zhang, B.**; Liu, B.; Chen, D.; Setroikromo, R.; Haisma, H.J.; Quax, W.J. Histone deacetylase inhibitors sensitize TRAIL-induced apoptosis in colon cancer cells. *Cancers (Basel)*. 2019, 11, 1–15.

[2] **Zhang, B.***; van Roosmalen, I.A.M.*; Reis, C.R.; Setroikromo, R.; Quax, W.J. Death receptor 5 is activated by fucosylation in colon cancer cells. *FEBS Journal*. 2019, 286, 555–571.

[3] **Zhang, B.***; Chen, D.*; Dekker, F.; Quax, W.J. A Novel Histone Acetyltransferase Inhibitor A485 Improves Sensitivity of Lung Cancer Cells to TRAIL. *Biochemical Pharmacology*. 2020, *in press*

[4] **Zhang, B.**; Chen, D.; Dekker, F.; Quax, W.J. Improved TRAIL-induced apoptosis in cancers by interfering with histone modifications. (In submission)

[5] Setroikromo, R.*; **Zhang B.***; Reis, C.R.; Mistry, R.; van Roosmalen, I.A.M.; Quax, W.J. Death Receptor 5 Displayed on Extracellular Vesicles Decreases TRAIL sensitivity of Colon Cancer Cells. *Frontiers in Cell and Developmental Biology*, 2020, *in press*

[6] **Zhang, B.**; He, D.; Fan, Y.; Liu, N.; Chen, Y. Oral delivery of exenatide via microspheres prepared by cross-linking of alginate and hyaluronate. *PLoS One* 2014, 9, 1–7.

[7] Zhang, J.; Tao, S.; **Zhang, B.**; Wu, X.; Chen, Y. Microparticle-based strategy for controlled release of substrate for the biocatalytic preparation of l -homophenylalanine. *ACS Catalysis* 2014, 4, 1584–1587.

(* authors contribute equally to this work)